| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C15H18Cl2N2O2S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
ML-9 is a selective, potent inhibitor of Akt kinase that also inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. It inhibits MLCK, PKA and PKC activity with Ki values of 4 μM, 32 μM and 54 μM, respectively[1], and it induces autophagy by stimulating autophagosome formation while inhibiting autophagosome degradation[3]. It is supplied as an off-white to light yellow solid (C15H18Cl2N2O2S, MW 361.29) at 99.86% purity.
Physical & Chemical Properties
| CAS Number | 105637-50-1 |
|---|---|
| Molecular Formula | C15H18Cl2N2O2S |
| Molecular Weight | 361.29 g/mol |
| Purity | 99.86% |
| Appearance | Solid |
| Color | Off-white to light yellow |
| SMILES | O=S(N1CCNCCC1)(C2=C3C=CC=C(Cl)C3=CC=C2)=O.[H]Cl |
| Signaling Pathway | Cytoskeleton |
| Solubility | In Vitro: DMSO: 83.33 mg/mL (230.65 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: ≥ 5 mg/mL (13.84 mM) * "≥" means soluble, but saturation unknown. |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 83.33 mg/mL (230.65 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | ≥ 5 mg/mL (13.84 mM) | — |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.76 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (5.76 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (5.76 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
ML9 at 0-100 μM for 0-24 hours does not reduce cardiomyocyte viability, whereas 50-100 μM significantly induces cell death[2]. At 50 μM for 1-4 hours, ML9 significantly raises cleaved caspase-3 levels and lowers STIM1 protein levels by about 42%[2].
Cell Viability Assay[1]
| Cell Line | Neonatal rat ventricular myocytes (NRVM) cells |
|---|---|
| Concentration | 0, 10, 50 and 100 μM |
| Incubation Time | 0, 1, 4, 8 and 24 hours |
| Result | Decreased cell viability at 50-100 μM concentration. |
Apoptosis Analysis[1]
| Cell Line | Neonatal rat ventricular myocytes (NRVM) cells |
|---|---|
| Concentration | 50 μM |
| Incubation Time | 1, 4 and 8 hours |
| Result | Induced cardiomyocyte death through necrosis and apoptosis. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Novel mechanisms of metformin-induced vasorelaxation of mesenteric arterioles via endothelium-dependent hyperpolarization to treat murine colitis. Eur J Pharmacol 2025 Sep 15:1003:177900. PMID: 40617384
Drug repurposing DMSO from an old solvent to a new candidate for the treatment of colitis and sepsis in male mice. Cell Calcium 2026 May 23:136:103155. PMID: 42235215
High-throughput assessment identifying major platelet Ca2+ entry pathways via tyrosine kinase-linked and G protein-coupled receptors. Cell Calcium 2023 Jun:112:102738. PMID: 37060673
JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle. Life Sci Alliance 2024 Aug 9;7(11):e202402885. PMID: 39122555
N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine induces endothelium-dependent hyperpolarization-mediated vasorelaxation via store-operated calcium entry mechanism in healthy and intestinal inflammatory mice. Heliyon 2024 Jul 6;10(14):e33994. PMID: 39108891
bioRxiv. 2023 Feb 5.
